Arkolith/Insider Trading/ACRS/Form 4/A

Loerop James

Chief Business OfficerAclaris Therapeutics, Inc. (ACRS) · full profile →Form 4/A · filed Feb 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2026Option exercise(M)8K——173K
Feb 1, 2026Tax withholding(F)11K$3.51$38K177K
Feb 1, 2026Option exercise(M)11K——166K
Feb 1, 2026Option exercise(M)15K——188K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2026Option exercise(M)11K—$00
Feb 1, 2026Option exercise(M)8K—$08K
Feb 1, 2026Option exercise(M)15K—$030K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001781549-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML